LDS/Medical Tests/Dopamine beta-hydroxylase (DBH) Genetic Variations

Dopamine beta-hydroxylase (DBH) Genetic Variations

Dopamine beta-hydroxylase regulates dopamine levels by enzymatic degradation. Two polymorphisms (DBH5'-Ins/del and DBH 444 g/a) of the DBH gene have been isolated and associated with low DBH activity, cocaine-induced paranoia, and response to cocaine vaccine responsiveness. Although the variants in DBH are not associated with the incidence of schizophrenia or cocaine addiction, the delA haplotype is associated with positive symptoms and therapeutic non-response in schizophrenia. Thus, the DBH gene is not a causative factor in schizophrenia but may modulate psychotic symptoms, severity of the disorder, and therapeutic response to neuroleptic drugs.

The DBH 1368A allele has also been associated with higher quit rates compared to the G allele in patients undergoing smoking cessation therapy with bupropion or placebo (the genotypic effect was independent of therapy).

  • Screening for treatment-resistant schizophrenia and predicting response to smoking cessation therapy
  • Evaluation of dopamine availability; identifying patients with decreased dopamine availability
  • Identifying schizophrenic candidates for neuroleptic therapy
Patients with the delA genotype are more likely to experience positive symptoms and poor response to neuroleptic therapies in schizophrenia. Patients with the low expression DBH −1021C>T genotype are more likely to respond to cocaine vaccine therapy. Patients with the 1368A allele are more likely to successfully complete smoking cessation therapy.

1368A Genotype

Polymerase chain reaction followed by agarose gel electrophoresis for fragment analysis; real-time PCR with allele specific primer extension or ARMS; conventional sequencing; next-generation sequencing.

Whole blood, saliva, or buccal swab

Collected in lavender top tube (EDTA) or any anticoagulant collection devices.

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Dopamine, catecholamine, and serotonin levels; DRD2, Catechol-O-methyltransferase Genotyping (COMT), and OPRM1 genotyping; Drug monitoring.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Am J Med Genet B Neuropsychiatr Genet. 2003 Feb;117B(1):33-8. [PMID: 12555232]
  • ClinPharmacolTher. 2010 Dec; 88(6): 779–791. [PMID: 20981002]
  • Neurosci Lett. 2013 Apr 29;541: 29-33. [PMID: 23458673]
  • Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7): 944-5. [PMID: 17503472]